OTC analgesic alcohol warning health risk communication to be assessed in FDA study.
This article was originally published in The Tan Sheet
Executive Summary
OTC ANALGESIC ALCOHOL WARNING HEALTH RISK COMMUNICATION will be assessed in FDA's upcoming consumer survey of OTC drug labeling. The agency says in an Aug. 6 description of the proposed research that its purpose will be "to investigate how various methods of phrasing information in the alcohol warning influences consumers' perception of the product's risk." The study will assess the adequacy of the currently used labeling statement: "Alcohol Warning: If you generally consume three or more alcohol-containing drinks per day, you should consult your physician for advice on when and how you should take [this product] and other pain relievers."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning